ImmuCell Reports Q3 Preliminary Sales Of $8M, Up 46% YoY

ImmuCell Corporation (NASDAQ: ICCC) reported preliminary, unaudited sales of $8 million for Q3 2026, marking a 46% increase year-over-year. Domestic sales contributed $6.9 million, reflecting a 29.2% increase compared to the same period in 2025. For the nine months ending September 30, 2026, total sales reached $25.6 million, a 27.8% increase from the previous year.